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Introduction. Cardiovascular disease, and coronary heart disease (CHD) first 
and foremost, is one of the leading causes of mortality in developed countries of the 
world [1]. The prognosis for patients with coronary heart disease depends, 
predominantly, on the progression of coronary atherosclerosis (CA). The 
pathogenetic basis of CA is chronic systemic inflammation (CSI) [2]. CSI in CA is 
supported by induction of cytokine-associated pathways of intracellular signaling. 
The central component of CSI is the nuclear factor kappa B (NF-kB), the main 
activators of which are proinflammatory cytokines (CK), especially interleukin 1 (IL-
1) and tumor necrosis factor α (TNFα) [3, 4]. The effector unit of the CSI is CK Th1 
of the immune response type, involved in the formation and destabilization of the 
atheromatous plaque [5]. 
Due to structural and functional remodeling, activation of neuro-humoral 
systems and reactions involving inflammatory molecules in patients with coronary 
artery disease, the disruption of systolic function of the left ventricle (LV) is formed. 
The biomechanical reorganization of the heart causes changes in the expression of 
genes that mediate CSI, apoptotic reactions, etc. [6]. 
Therefore, it is expedient to study in detail the molecular mechanisms of 
atherogenesis in order to find new targets for pharmacological effects in CA and 
CHD. 
The aim of our research was to examine the relationship between the level of 
CSI and central hemodynamic disorders in patients with coronary heart disease. 
Materials and methods. An open clinical trial was conducted. 230 patients 
with CHD were examined: stable angina pectoris, II FC, CH 0-I (119 men and 111 
women aged 57 + 8.3 years) and 30 healthy subjects (control group). The criteria for 
inclusion in the study were the age of men and women (40-75 years), the presence of 
CHD: exertional angina of II FC in the absence of destabilization of the course for at 
least two months, the informed consent of the patient to participate in the study. The 
exclusion criteria were the presence of chronic heart failure higher than stage I, high 
blood pressure, complications of cardiac rhythm and conduction disorders, 
rheumatism, cancer, anemia, diabetes mellitus, renal and hepatic insufficiency. 
To achieve the aim of the research, patients’ blood was tested for levels of IL-1β 
and TNFα by the immune enzyme method; fibrinogen (FG) plasma levels – by weight 
method and echocardiography (echo) [7]. The global contractile ability of LV was 
estimated by the stroke volume (SV), the ejection fraction (EF), and the velocity of the 
blood flow (v) in the external path (EP) of the LV. The diastolic function of LV was 
investigated by recording the transmitral blood flow rates by the ratio of the velocities of 
the early (E) and late (L) diastolic filling of the LV (E / A), the delay time of early 
diastolic filling of the LV (DT) and the time of isovolumic LV relaxation (IVRT) [7]. 
Results. In patients with coronary heart disease, an increase in the 
concentration of pro-inflammatory CK was found in the blood: the TNFα level was 
8.48 + 2.15 pg / ml, and the level of IL-1β was 9.34 + 2.80 pg / ml. In 37.4% of 
patients with coronary heart disease, high levels of FG in the blood plasma were 
observed. 
In patients with coronary heart disease, EF of LV, SV and v of EP of LV were 
significantly lower in comparison with the group of healthy individuals (p <0.05). 
The ratio of transmitral blood flow phases in patients with coronary heart disease was 
disrupted – E / A <1, the DT value was increased (p <0.05), IVRT was delayed (p 
<0.05). The clinical evaluation of echo results showed that LV diastolic dysfunction 
was detected in 99% of patients with CHD by the type of relaxation disturbances, 
1.6% – by the type of pseudonormalization. 
The study of the ratio in the indices of central hemodynamics and CSI markers 
revealed the reverse correlation between EF of LV and TNFα (r = -0.340, p <0.05), 
EF of LV and FG (r = -0.3369, p <0.01), the E / A value and IL-1β (r = 0.333, p 
<0.05). 
Conclusion. The obtained results demonstrate the negative effect of CSI on the 
systolic and diastolic function of LV in patients with coronary heart disease. 
Prospects for further research. Further study of the levels of pro-
inflammatory CK and other markers of inflammation in patients with CA and CHD 
can be the basis for constructing a diagnostic algorithm to determine the predictors of 
destabilization of the course and progression of the specified pathology and the 
development of optimal pathogenetically substantiated therapies. 
Recommendations. It is expedient to use the levels of CK and FG in the blood 
as diagnostic and prognostic markers for assessing the course of coronary heart 
disease, the progression of CA and the effectiveness of therapeutic measures. 
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